Israel , August 25, 2026 – Uvision, a global leader in smart integrated systems and loitering munitions, today announced the appointment of Eyal Rubin as Chief Financial Officer (CFO), effective as of September 2026. Rubin joins Uvision as the company continues to build on strong business momentum and expansion of its global activities, supported by new orders, recent achievements in the U.S. market and the combat-proven operational performance of its products. 

Rubin brings nearly three decades of financial leadership and capital markets experience. He has served as CFO of several Nasdaq- and NYSE-listed companies, including Nasus Pharma, Protalix Biotherapeutics and BrainStorm Cell Therapeutics, and previously served as Vice President and Head of Corporate Treasury at Teva Pharmaceutical Industries. 

“We are pleased to welcome Eyal to the team. He joins Uvision at an important stage in the company’s development, following major new orders, important wins in the U.S. and the combat-proven operational performance of our products,” said Dr. Ran Gozali, CEO of Uvision. “His extensive financial and capital markets experience will be an asset as we continue to grow and evaluate the strategic opportunities ahead. I would also like to thank Ronny Barak for his significant contribution and for the important role he has played in the company’s growth and we wish him every success in the future.”

“I am pleased to join Uvision at this exciting stage of its growth,” said Eyal Rubin, CFO of Uvision. “Uvision has established a strong position in the global defense market. I look forward to working with the management team and contributing my experience to Uvision’s continued development.”

Rubin holds a BA in Finance and Information Systems from the College of Management Academic Studies and an MBA in Finance from Bar-Ilan University, both summa cum laude.